{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T07:51:55Z","timestamp":1792050715247,"version":"4.4.0"},"reference-count":41,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Optimizing irradiation volumes and evaluating the effect of dose escalation on total and fractionated doses are critical for improving outcomes in high-grade glioma (HGG).<\/jats:p><\/jats:sec>Objective<\/jats:title>To assess the efficacy of modified target delineation guided by multimodal magnetic resonance imaging and white matter tracts combined with moderately hypofractionated simultaneous boost intensity-modulated radiotherapy (HSIB-IMRT) in patients with newly diagnosed HGG.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This single-center, 2-arm, open-label randomized clinical trial enrolled 154 patients aged 18 to 70 years with histologically confirmed, newly diagnosed HGG at a Chinese medical center from January 1, 2018, to August 31, 2022. Follow-up was completed in June 2024.<\/jats:p><\/jats:sec>Interventions<\/jats:title>Patients were randomized to receive modified target delineation guided by multimodal magnetic resonance imaging and white matter tracts combined with HSIB-IMRT (experimental arm) or standard IMRT per guideline recommendations (standard arm). Both arms received concurrent and adjuvant temozolomide chemotherapy.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary end point was progression-free survival (PFS). The secondary end point was overall survival (OS).<\/jats:p><\/jats:sec>Results<\/jats:title>Among 154 enrolled patients (76 in the experimental arm and 78 in the standard arm; 85 [55.2%] male; median [range] age, 51.5 [23.0-70.0] years), the median (range) follow-up duration was 22 (4-76) months, with 96 deaths by June 2024. The median PFS was 15.5 months (95% CI, 11.7-19.3 months) in the experimental arm and 13.5 months (95% CI, 8.7-18.3 months) in the standard arm (P<\/jats:italic>\u2009=\u2009.89). The median OS was 27.0 months (95% CI, 13.9-40.1 months) in the experimental arm and 21.0 months (95% CI, 18.0-24.0 months) in the standard arm (P<\/jats:italic>\u2009=\u2009.24). The clinical target volume in the experimental arm (CTV1: median [range], 116.7 [20.2\u2013370.7 cm3<\/jats:sup>]; CTV2: median [range], 174.4 [34.5-463.2 cm3<\/jats:sup>]) was significantly smaller than the clinical target volume in the standard arm (median [range], 225.0 [70.2-542.1 cm3<\/jats:sup>]; P<\/jats:italic>\u2009&amp;lt;\u2009.001). Recurrence rates within, outside, and multicentric to the target volume were comparable between arms. Grade 3 or 4 adverse events occurred in 4 patients (5.3%) in the experimental arm and 3 (3.8%) in the standard arm (P<\/jats:italic>\u2009=\u2009.72).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this randomized clinical trial, modified target delineation with HSIB-IMRT demonstrated comparable PFS and OS to standard IMRT in patients with newly diagnosed HGG, while significantly reducing the irradiation target volume without increasing the recurrence rates outside the target volume. These results suggest valuable insights for future research aimed at personalized, reduced volume strategies to optimize outcomes and minimize neurotoxicity in HGG.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ChiCTR.org.cn Identifier: ChiCTR1800014396<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.23053","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T15:31:09Z","timestamp":1753371069000},"page":"e2523053","source":"Crossref","is-referenced-by-count":8,"title":["Modified Target Delineation and Moderately Hypofractionated Radiotherapy for High-Grade Glioma"],"prefix":"10.1001","volume":"8","author":[{"given":"Liangzhi","family":"Zhong","sequence":"first","affiliation":[{"name":"Cancer Research Institute of the Chinese People\u2019s Liberation Army, Xinqiao Hospital, Army Medical University, Chongqing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pu","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shapingba Hospital affiliated to Chongqing University, Chongqing University, Chongqing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Chen","sequence":"additional","affiliation":[{"name":"Cancer Research Institute of the Chinese People\u2019s Liberation Army, Xinqiao Hospital, Army Medical University, Chongqing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diangang","family":"Chen","sequence":"additional","affiliation":[{"name":"Cancer Research Institute of the Chinese People\u2019s Liberation Army, Xinqiao Hospital, Army Medical University, Chongqing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Radiology, Xinqiao Hospital, Army Medical University, Chongqing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinwei","family":"Diao","sequence":"additional","affiliation":[{"name":"Department of Pathology, Xinqiao Hospital, Army Medical University, Chongqing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anmei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Cancer Research Institute of the Chinese People\u2019s Liberation Army, Xinqiao Hospital, Army Medical University, Chongqing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixing","family":"Gao","sequence":"additional","affiliation":[{"name":"Cancer Research Institute of the Chinese People\u2019s Liberation Army, Xinqiao Hospital, Army Medical University, Chongqing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangpeng","family":"Chen","sequence":"additional","affiliation":[{"name":"Cancer Research Institute of the Chinese People\u2019s Liberation Army, Xinqiao Hospital, Army Medical University, Chongqing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqin","family":"Li","sequence":"additional","affiliation":[{"name":"Cancer Research Institute of the Chinese People\u2019s Liberation Army, Xinqiao Hospital, Army Medical University, Chongqing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaojiang","family":"Huang","sequence":"additional","affiliation":[{"name":"Cancer Research Institute of the Chinese People\u2019s Liberation Army, Xinqiao Hospital, Army Medical University, Chongqing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Niu","sequence":"additional","affiliation":[{"name":"Cancer Research Institute of the Chinese People\u2019s Liberation Army, Xinqiao Hospital, Army Medical University, Chongqing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchun","family":"Pei","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Xinqiao Hospital, Army Medical University, Chongqing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guolong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Xinqiao Hospital, Army Medical University, Chongqing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengqing","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Xinqiao Hospital, Army Medical University, Chongqing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanghui","family":"Li","sequence":"additional","affiliation":[{"name":"Cancer Research Institute of the Chinese People\u2019s Liberation Army, Xinqiao Hospital, Army Medical University, Chongqing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"issue":"4","key":"zoi250671r1","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.prro.2016.03.007","article-title":"Radiation therapy for glioblastoma: executive summary of an American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline.","volume":"6","author":"Cabrera","year":"2016","journal-title":"Pract Radiat Oncol"},{"issue":"1","key":"zoi250671r2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s11060-019-03152-9","article-title":"NRG brain tumor specialists consensus guidelines for glioblastoma contouring.","volume":"143","author":"Kruser","year":"2019","journal-title":"J Neurooncol"},{"issue":"8","key":"zoi250671r3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.30833","article-title":"Cognitive symptoms across diverse cancers.","volume":"7","author":"Mayo","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zoi250671r4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/brain\/63.1.1","article-title":"The forms of growth in gliomas and their practical significance.","volume":"63","author":"Scherer","year":"1940","journal-title":"Brain"},{"issue":"7","key":"zoi250671r5","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/S1474-4422(24)00160-1","article-title":"Glioblastoma and brain connectivity: the need for a paradigm shift.","volume":"23","author":"Salvalaggio","year":"2024","journal-title":"Lancet Neurol"},{"issue":"2","key":"zoi250671r6","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1148\/radiol.2322030959","article-title":"Peritumoral brain regions in gliomas and meningiomas: investigation with isotropic diffusion-weighted MR imaging and diffusion-tensor MR imaging.","volume":"232","author":"Provenzale","year":"2004","journal-title":"Radiology"},{"issue":"1","key":"zoi250671r7","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s13014-018-1078-y","article-title":"Predicting patterns of failure in temporal lobe GBMs: possible implications on radiotherapy treatment portals.","volume":"13","author":"Jayamanne","year":"2018","journal-title":"Radiat Oncol"},{"issue":"11","key":"zoi250671r8","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.","volume":"28","author":"Wen","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi250671r9","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S0360-3016(03)00819-8","article-title":"The use of hypofractionated intensity-modulated irradiation in the treatment of glioblastoma multiforme: preliminary results of a prospective trial.","volume":"58","author":"Sultanem","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"zoi250671r10","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13014-019-1305-1","article-title":"Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience.","volume":"14","author":"Zhong","year":"2019","journal-title":"Radiat Oncol"},{"issue":"6","key":"zoi250671r11","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization classification of tumors of the central nervous system: a summary.","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol"},{"issue":"8","key":"zoi250671r12","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.cortex.2008.05.004","article-title":"A diffusion tensor imaging tractography atlas for virtual in vivo dissections.","volume":"44","author":"Catani","year":"2008","journal-title":"Cortex"},{"issue":"10","key":"zoi250671r13","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi250671r14","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/neuonc\/nox029","article-title":"The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria.","volume":"19","author":"Nayak","year":"2017","journal-title":"Neuro Oncol"},{"issue":"5","key":"zoi250671r15","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","article-title":"Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC).","volume":"31","author":"Cox","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"zoi250671r16","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3340\/jkns.2008.44.4.222","article-title":"The outcomes of concomitant chemoradiotherapy followed by adjuvant chemotherapy with temozolomide for newly diagnosed high grade gliomas: the preliminary results of single center prospective study.","volume":"44","author":"Choi","year":"2008","journal-title":"J Korean Neurosurg Soc"},{"issue":"2","key":"zoi250671r17","first-page":"107","article-title":"The outcomes of concomitant radiation plus temozolomide followed by adjuvant temozolomide for newly diagnosed high grade gliomas: the preliminary results of single center prospective study.","volume":"21","author":"Shawky","year":"2009","journal-title":"J Egypt Natl Canc Inst"},{"issue":"1","key":"zoi250671r18","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/neuonc\/noac099","article-title":"Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial.","volume":"25","author":"Omuro","year":"2023","journal-title":"Neuro Oncol"},{"issue":"11","key":"zoi250671r19","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1093\/neuonc\/noac116","article-title":"Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter.","volume":"24","author":"Lim","year":"2022","journal-title":"Neuro Oncol"},{"issue":"8","key":"zoi250671r20","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.","volume":"370","author":"Chinot","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi250671r21","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.3390\/cancers13051063","article-title":"Advanced imaging techniques for radiotherapy planning of gliomas.","volume":"13","author":"Castellano","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"zoi250671r22","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12885-019-5317-x","article-title":"Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging.","volume":"19","author":"Laprie","year":"2019","journal-title":"BMC Cancer"},{"issue":"15","key":"zoi250671r23","doi-asserted-by":"publisher","first-page":"14090","DOI":"10.1200\/JCO.2018.36.15_suppl.e14090","article-title":"Hypofractionated accelerated radiotherapy (HART) with concurrent and maintenance temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM).","volume":"36","author":"Mallick","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi250671r24","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1093\/neuonc\/noad119","article-title":"Randomized phase III trial of metabolic imaging-guided dose escalation of radio-chemotherapy in patients with newly diagnosed glioblastoma (SPECTRO GLIO trial).","volume":"26","author":"Laprie","year":"2024","journal-title":"Neuro Oncol"},{"issue":"4","key":"zoi250671r25","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.ijrobp.2014.07.014","article-title":"Radiation therapy dose escalation for glioblastoma multiforme in the era of temozolomide.","volume":"90","author":"Badiyan","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"zoi250671r26","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ijrobp.2008.04.030","article-title":"Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis.","volume":"73","author":"Panet-Raymond","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"zoi250671r27","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.ijrobp.2005.12.005","article-title":"Hypofractionated high-dose irradiation for the treatment of malignant astrocytomas using simultaneous integrated boost technique by IMRT.","volume":"64","author":"Iuchi","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"zoi250671r28","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.53285","article-title":"Adjuvant temozolomide chemotherapy with or without interferon alfa among patients with newly diagnosed high-grade gliomas: a randomized clinical trial.","volume":"6","author":"Guo","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"8","key":"zoi250671r29","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1093\/neuonc\/nox025","article-title":"Is more better? the impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology\/RTOG.","volume":"19","author":"Blumenthal","year":"2017","journal-title":"Neuro Oncol"},{"issue":"15","key":"zoi250671r30","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1212\/WNL.0000000000003809","article-title":"Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma.","volume":"88","author":"Gramatzki","year":"2017","journal-title":"Neurology"},{"issue":"8","key":"zoi250671r31","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma.","volume":"370","author":"Gilbert","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"zoi250671r32","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3171\/jns.1987.66.6.0865","article-title":"Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms.","volume":"66","author":"Kelly","year":"1987","journal-title":"J Neurosurg"},{"issue":"2","key":"zoi250671r33","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s13311-016-0507-6","article-title":"Modified criteria for radiographic response assessment in glioblastoma clinical trials.","volume":"14","author":"Ellingson","year":"2017","journal-title":"Neurotherapeutics"},{"issue":"4","key":"zoi250671r34","doi-asserted-by":"publisher","first-page":"559","DOI":"10.3171\/jns.1991.75.4.0559","article-title":"Malignant astrocytomas: focal tumor recurrence after focal external beam radiation therapy.","volume":"75","author":"Liang","year":"1991","journal-title":"J Neurosurg"},{"issue":"4","key":"zoi250671r35","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1227\/NEU.0000000000001183","article-title":"Individualized map of white matter pathways.","volume":"79","author":"Tun\u00e7","year":"2016","journal-title":"Neurosurgery"},{"issue":"9","key":"zoi250671r36","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1093\/neuonc\/nov113","article-title":"High-definition fiber tractography for the evaluation of perilesional white matter tracts in high-grade glioma surgery.","volume":"17","author":"Abhinav","year":"2015","journal-title":"Neuro Oncol"},{"issue":"2","key":"zoi250671r37","doi-asserted-by":"publisher","first-page":"127","DOI":"10.23736\/S0390-5616.18.04597-6","article-title":"Preoperative surgical planning of glioma: limitations and reliability of fMRI and DTI tractography.","volume":"63","author":"Conti Nibali","year":"2019","journal-title":"J Neurosurg Sci"},{"issue":"1","key":"zoi250671r38","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ijrobp.2006.12.009","article-title":"Evaluation of peritumoral edema in the delineation of radiotherapy clinical target volumes for glioblastoma.","volume":"68","author":"Chang","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"zoi250671r39","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.2008.19.4969","article-title":"Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status.","volume":"27","author":"Brandes","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"zoi250671r40","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.radonc.2010.08.020","article-title":"Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide.","volume":"97","author":"Minniti","year":"2010","journal-title":"Radiother Oncol"},{"issue":"5","key":"zoi250671r41","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/j.ijrobp.2021.03.032","article-title":"Initial results of a phase 2 trial of 18F-DOPA PET-Guided Dose-Escalated Radiation Therapy for Glioblastoma.","volume":"110","author":"Laack","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2836783\/zhong_2025_oi_250671_1755887455.75088.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T15:00:19Z","timestamp":1756306819000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2836783"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.23053","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]}}}